Brodalumab in psoriatic arthritis (PsA): 24-week results from the phase III AMVISON-1 and -2 trials

McInnes, I, Mease, P, Hjuler, KF et al. (2 more authors) (2019) Brodalumab in psoriatic arthritis (PsA): 24-week results from the phase III AMVISON-1 and -2 trials. In: Journal of the American Academy of Dermatology. AAD 2019: American Academy of Dermatology Annual Meeting, 01-05 Mar 2019, Washington, DC, USA. Elsevier , AB28-AB28.

Metadata

Item Type: Proceedings Paper
Authors/Creators:
  • McInnes, I
  • Mease, P
  • Hjuler, KF
  • Raymond, K
  • Helliwell, P
Copyright, Publisher and Additional Information:

© 2019 Published by Mosby, Inc. This is an author produced version of a paper published in Journal of The American Academy of Dermatology. Uploaded in accordance with the publisher's self-archiving policy.
Dates:
  • Published: October 2019
  • Published (online): 21 August 2019
  • Accepted: 1 November 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Inflammatory Arthritis (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 28 Nov 2019 15:23
Last Modified: 21 Aug 2020 00:38
Status: Published
Publisher: Elsevier
Identification Number: 10.1016/j.jaad.2019.06.140
Open Archives Initiative ID (OAI ID):

Export

Statistics


CORE (COnnecting REpositories)